Lemborexant

證據等級: L5

預測適應症: 1 個

Lemborexant: From Insomnia Disorder to Sleep Initiation and Maintenance Disorder

One-Sentence Summary

Lemborexant is a dual orexin receptor antagonist (DORA) approved in the United States, Japan, and Canada for the treatment of adult patients with insomnia disorder. The TxGNN model predicts it may be effective for Sleep Disorder, Initiating and Maintaining Sleep with a confidence score of 99.75%, supported by 1 registered clinical trial and 20 publications — including multiple Phase 3 RCTs establishing strong clinical evidence.

Quick Overview

Item	Content
Original Indication	Insomnia disorder (approved in US/Japan/Canada; not yet licensed in India)
Predicted New Indication	Sleep Disorder, Initiating and Maintaining Sleep
TxGNN Prediction Score	99.75%
Evidence Level	L1 (≥2 completed Phase 3 RCTs confirmed in literature)
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured dataset. However, based on extensive published literature, Lemborexant is a dual orexin receptor antagonist (DORA) that competitively and reversibly blocks both OX1R and OX2R (orexin receptors 1 and 2), with greater affinity at OX2R. By blocking orexin signalling — the brain’s primary arousal-promoting system — lemborexant reduces hyperarousal states and facilitates sleep onset and maintenance without causing the sedative suppression associated with benzodiazepines or Z-drugs.

The predicted indication, “sleep disorder, initiating and maintaining sleep,” is mechanistically identical to the approved indication in the US (FDA, December 2019), Japan (PMDA, 2020), and Canada. The orexin system is well-established as the central regulator of the sleep-wake transition; patients with insomnia disorder exhibit abnormally elevated orexin tone, and DORA therapy directly addresses this pathophysiology. This makes the TxGNN prediction highly coherent with established pharmacology.

It is worth noting that this TxGNN prediction does not represent a true “new” repurposing scenario — rather, it reflects a regulatory gap: lemborexant has robust multi-national approval but has not yet entered the Indian market. The prediction score of 99.75% and the breadth of supporting evidence make this one of the strongest candidates for market entry consideration.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06928766	Phase 2	Not Yet Recruiting	15	Double-blind, placebo-controlled RCT (ELOSA) comparing eszopiclone and lemborexant in patients with obstructive sleep apnoea (OSA) who have comorbid insomnia (COMISA) with low arousal threshold; targets a challenging population underserved by conventional therapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31880796	2019	RCT (Phase 3)	JAMA Network Open	Phase 3 RCT demonstrating lemborexant superiority over placebo and zolpidem ER in older adults with insomnia disorder; established pivotal efficacy and safety in a high-need population
32585700	2020	RCT (Phase 3)	Sleep	SUNRISE 2 trial: long-term (12-month) superiority of lemborexant vs. placebo for insomnia disorder; primary endpoint of subjective sleep onset and maintenance met
33636648	2021	RCT (Phase 3)	Sleep Medicine	12-month effectiveness and safety follow-up from SUNRISE-2 (Study 303); confirmed durable efficacy with favourable tolerability over extended treatment
35843245	2022	Systematic Review & NMA	The Lancet	Large NMA across pharmacological insomnia interventions in adults; lemborexant ranked among top agents for both acute and long-term management
36701954	2023	Systematic Review & NMA	Sleep Medicine Reviews	NMA of 20 insomnia drugs comparing efficacy and tolerability; lemborexant demonstrated favourable balance of sleep latency reduction and wake-after-sleep-onset improvement
40555730	2025	Systematic Review & NMA	Translational Psychiatry	Head-to-head NMA of three approved DORAs (daridorexant, lemborexant, suvorexant); provides updated risk-benefit appraisal supporting clinical utility of lemborexant
34121443	2021	Systematic Review & NMA	JMCP	NMA comparing lemborexant with other insomnia treatments; lemborexant showed superior efficacy across multiple sleep endpoints, particularly in older adults
32531478	2020	Systematic Review & NMA	Journal of Psychiatric Research	NMA directly comparing lemborexant and suvorexant; lemborexant showed numerically greater improvement in subjective sleep onset latency and total sleep time at Week 1
39277609	2024	Systematic Review	Translational Psychiatry	Systematic review of DORAs (lemborexant and suvorexant) for insomnia comorbid with psychiatric disorders (depression, bipolar disorder, substance use); supports use as independent insomnia treatment
32096020	2020	Drug Approval Review	Drugs	Comprehensive first-approval review summarising clinical pharmacology, Phase 2/3 trial data, and regulatory history of lemborexant (DAYVIGO™); confirms FDA approval December 2019

India Market Information

No marketing authorisations for Lemborexant are currently registered in India. The drug is approved and commercially available in the United States (FDA, 2019), Japan (PMDA, 2020), and Canada, but has not yet received CDSCO approval or entered the Indian market.

Safety Considerations

Drug Interactions (160 interactions identified; key interactions listed below):

Lemborexant is primarily metabolised via CYP3A4. The following interactions warrant clinical attention:

Interacting Drug	Severity	Clinical Relevance
Clarithromycin	Major	Strong CYP3A4 inhibitor; may significantly increase lemborexant exposure
Clotrimazole	Major	CYP3A4 inhibitor; increased sedation risk
Cimetidine	Major	CYP3A4/CYP2C19 inhibition; may elevate plasma levels
Aprepitant	Major	Combined CYP3A4 inhibitor/inducer; complex interaction profile
Morphine	Major	CNS depressant combination; additive sedation and respiratory depression risk
Morphine (liposomal)	Major	Same mechanism as morphine; enhanced CNS depression
Ranitidine	Major	Potential PK interaction; monitor for enhanced sedation
Pioglitazone	Moderate	CYP2C8 involvement; monitor for altered glucose control
Bupropion	Moderate	CNS effects may be additive; monitor for increased adverse effects
Dexamethasone	Moderate	CYP3A4 inducer; may reduce lemborexant efficacy

Detailed warnings and contraindications are not available in the current data pack. Please refer to the US FDA prescribing information (DAYVIGO™ label) and Japanese PMDA package insert for comprehensive safety information pending CDSCO label availability.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Lemborexant has Level 1 evidence (multiple completed Phase 3 RCTs published in high-impact journals) and is already approved by three major regulatory authorities (FDA, PMDA, Health Canada), making its efficacy and safety profile well-established. The TxGNN prediction (99.75%) correctly identifies its primary approved indication, confirming model validity. The barrier to use in India is regulatory, not evidentiary.

To proceed, the following is needed:

CDSCO regulatory submission: File a New Drug Application (NDA) with CDSCO under Rule 122E, leveraging existing FDA/PMDA approvals for expedited review
India-specific labelling: Obtain full CDSCO-approved prescribing information including local warnings, contraindications, and special population guidance
Mechanism of action data: Complete the MOA data gap (DG002) by retrieving DrugBank structured pharmacology entry for DB11951
TFDA package insert review: Resolve data gap DG001 — download and parse the prescribing information to enable full safety assessment
Post-marketing pharmacovigilance plan: Establish local adverse event monitoring consistent with CDSCO Schedule Y requirements
Local PK bridging consideration: Assess whether CYP3A4 metabolic variability in the Indian population requires dose adjustment studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.